October 23rd 2023
Celltrion’s Zymfentra is subcutaneous version of infliximab.
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Biosimilars to AMD Drugs: The Obstacles In Their Way
March 4th 2022Off-label Avastin, Eylea and Lucentis are the primary treatments for neovascular age-related macular degeneration (AMD), a leading cause of blindness. A recent review article looked at the impediments to the biosimilars for these drugs Ophthalmologists are wary about using biosimilars to Avastin (which was approved as a cancer drug) for AMD. Biosimilars to Eylea and Lucentis are not on the market yet. Manufacturers’ rebates and Medicare Part B “buy and bill” policies could make it difficult for them to compete against their brand-name “originator” products.
Read More
Viatris is Getting Out of Biosimilars Business… But Not Completely
March 3rd 2022The company announced this week that it is selling its biologics unit to Biocon Biologics, but Viatris is also slated to have a stake in the biosimilars entity that will bring together Biocon Biologic’s biosimilar operations and those that Viatris is selling off.
Read More
Study: Here’s Some Evidence That Switching Among Generic Levothyroxine Products Is OK
March 1st 2022Guidelines tell prescribers and patients to avoid switching among levothyroxine products from different manufacturers. But Mayo Clinc-led research finds little difference between switchers and nonswitchers.
Read More
Top 4 Biosimilar Developments of 2021
December 10th 20212021 was an outstanding year for biosimilar medications, as they increased market share and adoption by healthcare providers and the first biosimilar and interchangeable insulin was approved by the FDA. Take a look at Managed Healthcare Executive's top four biosimilar developments of 2021.
Read More
Priming the Pump for Interchangeable Biosimilars By Preferencing Semglee
November 4th 2021By giving Semglee, the interchangeable biosimilar for Lantus, a preferred spot on its formulary, the Prime Therapeutics says it is setting the stage for other interchangeables coming down the pike, including the one for Humira.
Read More
Biosimilar Growth Impressive But New Policies Needed, AAM Exec Says
October 8th 2021Three pieces of legislation that would provide incentives to prescribers and put generics and biosimilars in favorable formulary tiers would speed further prescribing and use of biosimilars, Christine Simmon told Managed Healthcare Executive.®
Read More
AAO Spokesperson: FDA Approval of Byooviz, First Biosimilar to Lucentis, Is “Significant"
October 7th 2021Exactly how Byooviz will be priced is unclear, noted George W. Williams, M.D., a retina specialist and past president of the American Academy of Ophthalmology. The exact cost savings will help determine whether the biosimilar gains acceptance.
Read More
Rituximab Biosimilars Produce Big Cost Savings, are Effective
September 7th 2021A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43% reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.
Read More
In this second part of a two-part video series, Briana Contreras, associate editor of MHE caught up with MHE Editorial Advisory Board member David Calabrese, who is market president of Health Plans/PBMs at OptumRx. Calabrese shared his thoughts on the approval of the Alzheimer’s drug Aduhelm, as well as the Biden Administration's interest in putting more generics and biosimilars in the market.
Watch
The Generic, Biosimilar Medicine Industry Today and What it Can Become in The Next Decade
July 14th 2021International Generic and Biosimilar Medicines Association recently released the report, "A Vision for the Global Generic and Biosimilar Medicines Industry,” covering the current global Generic and Biosimilar medicine industry, and released a vision of what the market will be in 2030 and how to achieve it.
Read More
Generic Drug Price Tags: Too High. And Too Low. Competition Can Help Create an In-Between.
July 13th 2021Low prices and some gaming of regulations can drive out competitors and create monopolies that allow generic makers to jack up their prices. Experience has shown that it often takes multiple generics to achieve the promised-for downward pressure on prices.
Read More
While We Await Vaccine Progress, We Can Trust in Generic Drugs
February 1st 2021Generic drugs account for 90% of the prescriptions filled in the United States. They are the backbone of healthcare providers’ treatment protocol and they are remarkably cost effective: despite being 90% of the prescriptions filled, generics account for only 20% of drug spending.
Read More